# Glutamatergic Modulation of Disordered Alcohol Use

> **NCT02539511** · PHASE2,PHASE3 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 50 (actual)

## Conditions studied

- Alcohol Dependence

## Interventions

- **DRUG:** CI-581a
- **DRUG:** CI-581b
- **BEHAVIORAL:** Motivational Enhancement Therapy (MET)

## Key facts

- **NCT ID:** NCT02539511
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-09
- **Final completion:** 2017-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02539511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02539511, "Glutamatergic Modulation of Disordered Alcohol Use". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02539511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*